Bacterial Amyloid Peptides for Epithelial Permeability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory disorders of the epithelium, such as inflammatory bowel disease and psoriasis, often have significant side effects and do not effectively address the underlying inflammatory responses, necessitating a more targeted approach to manage epithelial permeability and immune homeostasis.
Innovation Solution
Administration of isolated bacterial amyloid peptides, specifically curli fibrils or recombinant bacteria encoding these peptides, to activate the TLR2/PI3K pathway, thereby decreasing epithelial permeability and modulating the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inflammatory disorders of the epithelium, then inflammatory symptoms may be suppressed, but significant side effects occur and underlying inflammatory responses are not effectively addressed
Solution Approach 1:
The patent converts the harmful effect of bacterial amyloids (which normally activate TLR2 and cause inflammation) into a beneficial therapeutic effect by using purified bacterial amyloid peptides to deliberately activate the TLR2/PI3K pathway. This controlled activation restores epithelial barrier function and modulates immune responses in inflammatory disorders, transforming a pathogenic mechanism into a therapeutic tool
Solution Approach 2:
The patent uses bacterial amyloid peptides as intermediary substances that mediate between the immune system and the epithelial barrier. These peptides specifically target and activate TLR2 receptors on epithelial cells, triggering downstream PI3K signaling that restores barrier function without causing the uncontrolled inflammation associated with conventional anti-inflammatory treatments
2Adaptability or versatility
If the intestinal epithelium is exposed to large amounts of bacterial antigens, then commensal bacteria growth is supported, but hyper-responsive inflammatory processes occur
Solution Approach 1:
The patent applies local quality by delivering bacterial amyloid peptides directly to the intestinal epithelium where they specifically activate TLR2 signaling in epithelial cells. This localized action restores barrier function at the site of inflammation without systemically suppressing immune responses, allowing commensal bacteria to thrive while preventing hyper-responsive inflammation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces bacterial translocation and induces anti-inflammatory cytokine production, providing a targeted treatment for inflammatory disorders by maintaining intestinal immune homeostasis and reducing hyper-responsive inflammatory processes.
Implementation Method 1
Administration of isolated bacterial amyloid peptides, specifically curli fibrils or recombinant bacteria encoding these peptides, to activate the TLR2/PI3K pathway
Data Source
AI summary
A method for treatment of a subject having an inflammatory disease of the epithelium comprising the step of administering an amount of a composition comprising an isolated bacterial amyloid peptide to said subject. In embodiments, the composition is membrane-free. In embodiments, the composition comprises a curli fibril. In yet further embodiments, the isolated bacterial amyloid peptide is a CsgA polypeptide, a CsgA polypeptide fragment, a CsgB polypeptide or a CsgB polypeptide fragment. Also provided is a method for decreasing epithelium permeability in a tissue of a subject comprising epithelium comprising the step of administering an amount of a composition comprising an isolated bacterial amyloid peptide to the epithelium of the subject. In embodiments, the composition is membrane-free. In further embodiments, the composition comprises a curli fibril. In embodiments, the isolated bacterial amyloid peptide is a CsgA polypeptide, a CsgA polypeptide fragment, a CsgB polypeptide or a CsgB polypeptide fragment.